ACR Recommendations for the Management of RA: 2021 Update
CR Recommendations for the Management of Rheumatic Arthritis: 2021 Update
Developed by CESAS Medical, under the auspices of the University of Glasgow This activity is supported by unrestricted educational grants from AbbVie, Gilead/Galapagos, Pfizer and Lilly
Release date: 06 August 2021
Estimated time to complete activity: 1 hour and 10 minutes
Compatible with all modern internet browsers and mobile devices
After completing this activity, the learner will:
Be familiar with the updated ACR recommendations for the management of RA
Understand the rationale for changes in the ACR recommendations for the management of RA
Understand the evolving role of JAK inhibitors in the treatment paradigm
Be aware of differences between the EULAR and ACR recommendations for the management of RA
This activity is designed for qualified rheumatologists of all levels of seniority, and other healthcare professionals involved in treating patients with inflammatory disease.
The updated ACR Recommendations for the Management of Rheumatoid Arthritis present the latest expert opinion on clinical treatment paradigms for optimal patient outcomes.
In this course, ACR Recommendations for Management of Rheumatic Arthritis: 2021 Update , experts highlight key revisions for the management of RA and discuss why changes were made from previous recommendations. Experts also review the differences between the EULAR and ACR recommendations for rheumatoid arthritis. The learner’s understanding of the information presented will be assessed following each of the course modules.
INSTRUCTIONS FOR PARTICIPATION
Participants must 1) read the activity information; 2) study the educational activity; 3) successfully complete the post-module assessments with a score of 80% or better; 4) and complete the evaluation form.
DISCLOSURE OF CONFLICTS OF INTEREST
CESAS Medical requires faculty, presenters, planners, managers, writers, and any other individuals who are in a position to influence the content of this activity to disclose any real and/or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly reviewed and resolved according to CESAS Medical policy.